Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

TY - JOUR

T1 - Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

AU - Barrington, Sally F

AU - Qian, Wendi

AU - Somer, Edward J

AU - Franceschetto, Antonella

AU - Bagni, Bruno

AU - Brun, Eva

AU - Almquist, Helén

AU - Loft, Annika

AU - Højgaard, Liselotte

AU - Federico, Massimo

AU - Gallamini, Andrea

AU - Smith, Paul

AU - Johnson, Peter

AU - Radford, John

AU - O'Doherty, Michael J

AU - Jakobsen, Annika Loft

AU - Smith, Paul

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. Methods Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/ dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). Results There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. Conclusion The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.

AB - Purpose To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. Methods Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/ dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). Results There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. Conclusion The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.

U2 - 10.1007/s00259-010-1490-5

DO - 10.1007/s00259-010-1490-5

M3 - Journal article

C2 - 20505930

SN - 1619-7070

VL - 37

SP - 1824

EP - 1833

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 10

ER -